pp-252 Solution for infusion
Dossier type
CTD
Dossier status
Under development
Country of origin
China
GMP approvals
China
Comments
Indication: Cervical cancer / Clinical stage: Phase 3 / Modality: Antibody-drug conjugate (ADC) / Mechanism & Target: Nectin-4 targeting ADC / Route & form: Intravenous infusion / Differentiation: First Nectin-4 targeting ADC in Phase 3 for cervical cancer globally
Manufacturer #38957
Founded in 2017, this clinical-stage biopharmaceutical company develops Rx antibody biologics for oncology, immunology, ophthalmology, and metabolic diseases. Injectable biologic pipeline is progressing through clinical stages with domestic approvals and an international development strategy. Engages in global licensing partnerships for co-development and commercialization.
Manufacturer usually replies in 31 days
None